---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-268003"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-11-29T23:59:59+00:00"
generated_at: "2026-05-29T12:42:02.079370+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics CEO Scott Wolchko to retire Dec 31; succeeded by Bob Valamehr

## Summary
- Wolchko resigned from board Nov 27, 2024; will retire as President & CEO effective Dec 31, 2024.
- Valamehr, currently President of R&D, becomes President & CEO Jan 1, 2025; also named director.
- Wolchko to remain a strategic advisor after retirement; resignation not due to any disagreement.
- Valamehr has led iPSC platform development ~15 years; oversaw 13 IND applications and pipeline.
- FT819 SLE trial: first patient achieved drug-free remission after single dose; no dose-limiting toxicities.

## SEC filing metadata
- accession: 0001193125-24-268003
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-11-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312524268003/0001193125-24-268003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312524268003/d816234d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-268003
- JSON: https://secwatch.observer/filing/0001193125-24-268003.json
- Plain text: https://secwatch.observer/filing/0001193125-24-268003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.